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Background: Mutations in the PTRF gene, coding for cavin-1, cause congenital generalized lipodystrophy type 4
(CGL4) associated with myopathy. In CGL4, symptoms are variable comprising, in addition to myopathy, smooth
and skeletal muscle hypertrophy, cardiac arrhythmias, and skeletal abnormalities. Secondary features are atlantoaxial
instability, acanthosis nigricans, hepatomegaly, umbilical prominence and metabolic abnormalities related to insulin
resistance, such as diabetes mellitus, hyperlipidemia and hepatic steatosis.
Case presentation: We describe a 3 year-old child of Moroccan origin with mild muscle phenotype, mainly
characterized by mounding, muscle pain, hyperCKemia and mild caveolin 3 reduction on muscle biopsy. No CAV3
gene mutation was detected; instead we found a novel mutation, a homozygous single base pair deletion, in the
PTRF gene. Only after detection of this mutation a mild generalized loss of subcutaneous fat, at first
underestimated, was noticed and the diagnosis of lipodystrophy inferred.
Conclusions: The PTRF gene should be investigated in patients with hyperCKemia, mild myopathy associated with
spontaneous or percussion-induced muscle contractions like rippling or mounding, and no CAV3 mutation. The
analysis should be performed even if cardiac or metabolic alterations are absent, particularly in young patients in
whom lipodystrophy may be difficult to ascertain.
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Congenital generalized lipodystrophies (CGLs) are auto-
somal recessive disorders characterized by almost complete
absence of body fat. Various gene defects may cause the
condition. Mutations in a new gene, PTRF (polymerase I
and transcript release factor), coding for cavin-1, have
recently been found to cause CGL type 4 (CGL4) associated
with muscle disease [1-3].
Cavin-1 is an abundant protein component of caveolae,
and member of a family of related proteins that form a
caveola- associated multiprotein complex. The complex
also contains serum deprivation response (SDR)/cavin-2,
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stated.(SRBC)/cavin-3, and muscle-restricted coiled-coil protein
(MURC)/cavin-4 [4-8].
This complex can constitutively assemble in cytosol and
associate with caveolin at plasma membrane caveolae.
Cavin-1, but not other cavins, can induce caveola formation
in a heterologous system and is required for recruitment of
the cavin complex to caveolae [9]. Absence of cavin-1 leads
to global loss of caveolae, and markedly diminished
expression of all three caveolin protein isoforms, while
caveolin mRNA levels are normal or above normal [10].
Cavin-1-knockout mice are viable and of normal
weight but have high circulating triglycerides, low adipose
tissue mass, glucose intolerance, and hyperinsulinemia
(lipodystrophic phenotype).
Few PTRF mutations have so far been reported in
humans [1-3,11,12]. We describe a 3-year-old boy with
mild muscular phenotype in whom lipodystrophy was
diagnosed only after detection of a novel homozygous
mutation in the PTRF gene.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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The boy is the fourth child of healthy consanguineous
(first cousins) parents of Moroccan origin. A sister and
brother are in good health but the other sister died 6 hours
after birth. Family history is negative for neuromuscular
diseases.
The patient was born after an uncomplicated pregnancy
with APGAR 8 at 1 minute and 9 at 5 minutes. He was
noticed to have supinated left foot varus, mild dysmorphic
features and reduced motility without hypotonia. Brain
and renal ultrasound, EEG, and karyotype were normal.
Normal psychomotor development was reported during
the first year, but by 18–20 months he had clumsy gait,
muscle pain in the lower limbs, mild fatigability and
elevated muscle enzymes (CK 1179–1589 IU/L, normal
24–195; LDH 446–697 IU/L, normal 230–480); ECG and
thyroid function tests were normal.
When next seen at 3 years 4 months, the boy had a
protruding abdomen, a marked umbilical prominence,
mild generalized loss of subcutaneous fat and no
acanthosis nigricans (Figure 1); his weight was 13 kg
(3rd to 10th centile), height 94 cm (50th centile).
Neurological examination showed normal cranial nerves,
normal tone, mild axial weakness, with difficulty in sitting
from supine position, but normal strength limb muscles,
hypertrophic buttock and lower limb muscles (Figure 1),Figure 1 Photographs of our patient. Protruding abdomen, marked umb
hypertrophic buttock and lower limb muscles are shown.reduced lower limb tendon reflexes, lumbar lordosis, supi-
nated left foot varus and clumsy gait. The patient was able
to get up from the chair and to stand up from the floor
without support. There was also marked and rapid
percussion-induced muscle contraction and mounding in
upper and lower limbs.
Cognitive development was normal. Muscle enzymes
were elevated: CK 963 (normal < 195 IU/L); LDH 767
(normal < 480 IU/L); AST 45 (normal < 41 IU/L); ALT
50 (normal < 37 IU/L); aldolase 19.2 IU/L (normal < 7.6).
Brain and cervical spinal cord MRI were normal; EMG
revealed mild myopathic alterations and absence of
myotonic discharges. Lower limb CT showed muscle
hypertrophy and marked loss of subcutaneous fat
(Figure 2). ECG was normal; abdominal ultrasonography
was normal: in particular liver and spleen enlargements
were excluded.
Muscle biopsy, after informed parental consent, showed
moderate variation in fiber size, fibers with central nuclei,
and mild endomysial fibrosis (Figure 3B). Muscle immu-
nostaining showed mildly reduced and variable expression
between fibers of caveolin-3 (Figure 3A), but CAV3 gene
sequencing failed to reveal any pathogenic mutation.
On sequencing the PTRF gene, a novel homozygous
single base pair deletion, c.947delA was found (Figure 3D);
the same mutation was present heterozygously in eachilical prominence, mild generalized loss of subcutaneous fat, and
Figure 2 Lower limb CT, showing muscle hypertrophy and marked loss of subcutaneous fat.
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healthy sister. The deletion was also detected in the cDNA
and results in a frame shift and in introduction of the
first stop codon 27 residues downstream of the correct
stop codon, so the predicted protein is larger than the
non-mutated protein (see ClustalW [13] predicted DNA
sequence in Additional file 1: Figure S1).
Immunostaining showed that cavin-1 was absent from
the sarcolemma with both antibodies used (Figure 3A).
Western Blot showed absence of the band corresponding
to cavin-1 (Figure 3C).
At the last visit, 14 months after diagnosis, clinical
examination was unchanged with regard to the presence
of generalized lypodistrophy; myopathic signs had
remained mild, while fatigability and axial weakness
were slightly improved and minimal acanthosis in the
knees was observed.
After diagnosis the child underwent cardiological and
metabolic evaluation. Echocardiogram was normal,
ECG-holter monitoring showed sinus arrhythmia andfew supraventricular extrasystoles, without evidence of QT
prolongation. Fasting glucose, glucose tolerance test, growth
hormone, cholesterol and triglyceride levels were normal.
Serum leptin level was undetectable and adiponectin
level was 0.83 μg/ml (normal 3–29 μg/ml). Finally,
the patient had no history of recurrent pneumonia, and
immunoglobulins were normal.
Discussion
There are few reports of PTRF gene mutations in the
literature [1-3,11,12]. They have been found in families of
Omani, UK, Japanese, Hispanic and Turkish origin. We
have found a new mutation in this gene in a mildly affected
child of Moroccan origin. CGL4 was not diagnosed at first,
and the PTRF gene was only investigated because muscle
hypertrophy was associated with marked muscle mounding
and CAV3 mutations were not found. After the mutation
had been detected, the patient was re-evaluated and
absence of adipose tissue noted, however the lipodystrophy
in this patient was mild and subtle.
Figure 3 Histological, immunochemical and molecular studies. (A) Immunohistochemistry showing mild and irregular reduction of caveolin
3 and absence of cavin-1 (Bar = 20 μm); (B) Gomori trichrome staining showing mild histopathologic changes (Bar = 20 μm); (C) immunoblot
showing absence of the band corresponding to cavin-1; (D) electropherograms showing homozygous single bp deletion in the patient, present
in a single copy in both parents.
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variable in CGL4, comprising myopathy, smooth and skel-
etal muscle hypertrophy, cardiac arrhythmias, and skeletal
abnormalities [3]. Secondary features are atlantoaxial in-
stability, hepatomegaly, mild metabolic complications such
as high circulating triglycerides and hyperinsulinism or dia-
betes, low leptin and adiponectin levels, reduction of
growth hormone levels, immunoglobulin A deficiency, and
umbilical prominence. Of these symptoms our patient had
mild myopathic signs, mainly characterized by axial weak-
ness, muscle hypertrophy, more evident in lower limbs,
diffuse muscle mounding, umbilical prominence and low
leptin and adiponectin levels. Other signs were absent. In
particular, cardiac function was essentially normal; however
the patient is still young and will require close monitoring
as he grows, since the cardiac arrhythmias typical of PTRF
mutated patients are potentially life-threatening: sudden
deaths have been reported in consanguineous Omani
families with PTRF mutations [14]. A case of similar age,
but with more severe clinical features, has been recentlydescribed by Murakami et al. [12]. Differently from our
patient, Murakami’s case had motor delay, more severe
muscle impairment, progressive metabolic abnormalities
and dystrophic changes on muscle biopsy.
Although the precise mechanism of muscle rippling
is unclear, some reports indicate that caveolin-3 has
a role in Ca2+ homeostasis. Loss of this protein leads
to microscopic disarray in the colocalization of voltage-
sensing dihydropyridine receptor and ryanodine receptor,
thereby reducing the efficiency of excitation-contraction
coupling [15].
As Cavin-1 is important in caveola formation and
associates with caveolins, including caveolin-3, it is
not surprising that mutations in cavin-1 cause muscle
rippling or mounding.
The mutation we found affects the C terminus and
creates a frame shift and a new stop codon 27 residues
downstream of the original stop codon, producing a
predicted protein of higher molecular weight. However,
immunohistochemistry and Western blot indicates that
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because it is unstable and immediately degraded.
Conclusions
To conclude, our 3-year-old boy with CGL4 had a mild
muscular phenotype mainly characterized by mounding,
muscle pain and hyperCKemia. We failed to detect a CAV3
mutation, but instead found a novel homozygous mutation
in PTRF. Our findings suggest that, in the presence of my-
opathy associated with spontaneous or percussion-induced
muscle contractions (rippling or mounding), mildly reduced
caveolin 3 expression and no CAV3 mutation, the PTRF
gene should be investigated, particularly in young patients
in whom lipodystrophy may be difficult to ascertain.
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